Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC-1245 in Unresectable, Locally Advanced, or Metastatic Cancer
NCT06678659Phase 2Recruiting
- Sponsor
- Recursion Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Oct 2028
- Modality
- Molecular Glues
- Countries
- 2
01
Overview
Phase 2, open-label trial of REC-1245 in solid tumor and lymphoma (9 arms), sponsored by Recursion Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Treatment-emergent Adverse Events at 24 months and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
REC-1245
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT06678659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678659.